Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing can supply psychological consolation to sufferers with breast most cancers and survivors in addition to perception...
The U.S. Meals and Drug Administration (FDA) has granted quick observe designation to IBI3003, an anti-GPRC5D/BCMA/CD3 tri-specific antibody, to expedite the event...
As folks with superior most cancers method the tip of life, therapy priorities typically shift from long-term illness prevention to consolation, symptom...
